Startups recycling composites into reusable fibers, developing multi-tissue test systems, highly-effective biomolecules, and a cloud-based platform for medical researchers each win CHF 10.000
02.11.2021
Composite Recycling, Fluosphera, KYLYS, and Publisher Pro win the first stage of Venture Kick entrepreneurial and financial support. Their projects design a post-treatment process to make the recovered fibers saleable and reusable for new composite materials, allow for a better prediction of the toxicity and safety of compounds, aim at providing people and patients with highly effective and safe products based on biomolecules, break writing tasks into small, manageable components, integrating them into the scientific process.
 |
 |
 Composite Recycling CEO Guillaume Perben, CSO Pascal Gallo, and CTO Mitchell Anderson
|
|
 FluoSphera CEO-CSO Gregory Segala and CTO Marie Shamseddin
|
|
 Kylys CEO Alexandre Porcello and CFO Bryan Porcello
|
|
 Publisher Pro team, from left to right: CFO Jason Best, CEO Kali Tal, Editorial Director Kirsti Cole, and Managing Director Kristin Bivens
|
|
Composite Recycling: Recycling Composites Into Reusable Fibers
Every year in Europe, around 100000 boats reach the end of their life. Until now the industry did not have a solution to recycle the glass fibers in a cost-effective way so the standard solution to treat the hulls was incineration into cement plants, burial into
landfills, or sunken to the bottom of the sea. Composite Recycling has developed a process that makes it possible to recover the glass fibers from GFRP intact. Founders CEO Guillaume Perben, CSO Dr. Pascal Gallo, CTO Dr. Mitchell Anderson, in collaboration with the group of Prof. Véronique Michaud at EPFL, designed a post-treatment process to make the recovered fibers saleable and reusable for new composite materials. The market for boats in Europe and North America alone is estimated to be 200 MCHF, with the perspective of recycling wind turbines, with a market potential of several billion CHF/year.
They will use the money from the first round of Venture Kick to finance the website, promotional material, travels to tradeshows and startup events, and meet with VCs and angels. composite-recycling.ch
Fluosphera: Multi-tissue test systems for a reliable prediction of toxicity
23% of all deaths worldwide are attributable to environmental exposures. Unfortunately, only 5% of chemical toxicity can be predicted because of the current limitations of in vitro testing. FluoSphera overcomes these limitations by producing multi-tissue test systems to recapitulate human body organization. Fluosphera's team is composed of Gregory Segala (CEO/CSO, future co-founder), Marie Shamseddin (CTO, future co-founder), and Advisory Board Prof. Aurélien Roux, Full Professor at UniGE, Dr. Dimitri Moreau, Director of ACCESS Geneva (HCS academic platform), and Robert Slooves, partner at Adya. Thanks to FluoSphera's disruptive technology (patent WO2021058557A1), life scientists get an unprecedented level of information at the physiological scale, with affordable products easy to use (kits containing vials of fluorescent-coded tissues). This allows for a better prediction of the toxicity and safety of compounds (drugs, chemicals, cosmetics, etc.) in any laboratory in order to better protect patients and consumers. With this technology, FluoSphera also plans to reduce animal testing and to improve the quality of water (SDG 6). They have evaluated the total market size of the multi-tissue test systems technology to 230 MCHF.
KYLYS: providing patients with highly effective and safe products based on biomolecules
Current hyaluronic acid-based dermal fillers used to correct volume deficiencies and improve facial contours have still several limitations. KYLYS focus on developing a unique dermal filler product with significant competitive advantages due to their innovative technology. KYLYS' team consists of Alexandre Porcello (CEO), Bryan Christopher Porcello (CFO), Dr. Si Gou (Product developer in the frame of the Innosuisse project), and 2 of the initial 3 Founders Dr. Olivier Jordan (CSO ad interim and scientific advisor), Prof. Eric Allémann (scientific advisor). Dr. Patrick Micheels and Dr. Denis Salomon joined the project as key opinion leaders in medical aesthetics. The activity of Kylys gained a brand new dynamic since Alexandre Porcello joined the team in 2020
and Bryan Christopher Porcello in 2021. They are now in charge of the full development of KYLYS. Their technology is already protected by a patent granted in the USA, and benefits from a worldwide I.P cover. The dermal filler products prototypes are developed under an ongoing Innosuisse project. The technology has shown relevant first prototypes with solid PoP/PoC, which brings the company to the status to raise the investment needed to go into the next development stages. This development stage corresponds to Technology Readiness Level 4, in the early development phase of the product. they are looking for Serie A financing for next year to complete all their pre-clinical tests and develop our insights about the market. The Dermal Fillers market size exceeded 3.73 billion in 2019 and is expected to be worth 6.64 billion by 2027 with a 9.3% CAGR.
The Venture Kick financing will support the development of KYLYS for the large-scale production of the product, a safety study in animals, with first steps towards CE marking, and through refinement of the business strategy, product positioning, team building. kylys.com
Publisher Pro: write better scientific papers 50% faster
Every year in Europe, around 100000 boats reach the end of their life. Until now the industry did not have a solution to recycle the glass fibers in a cost-effective way so the standard solution to treat the hulls was incineration into cement plants, burial into
landfills, or sunken to the bottom of the sea. Composite Recycling has developed a process that makes it possible to recover the glass fibers from GFRP intact. Founders CEO Guillaume Perben, CSO Dr. Pascal Gallo, CTO Dr. Mitchell Anderson, in collaboration with the group of Prof. Véronique Michaud at EPFL, designed a post-treatment process to make the recovered fibers saleable and reusable for new composite materials. The market for boats in Europe and North America alone is estimated to be 200 MCHF, with the perspective of recycling wind turbines, with a market potential of several billion CHF/year.
They will use the money from the first round of Venture Kick to finance the website, promotional material, travels to tradeshows and startup events, and meet with VCs and angels. composite-recycling.ch
Fluosphera: Multi-tissue test systems for a reliable prediction of toxicity
23% of all deaths worldwide are attributable to environmental exposures. Unfortunately, only 5% of chemical toxicity can be predicted because of the current limitations of in vitro testing. FluoSphera overcomes these limitations by producing multi-tissue test systems to recapitulate human body organization. Fluosphera's team is composed of Gregory Segala (CEO/CSO, future co-founder), Marie Shamseddin (CTO, future co-founder), and Advisory Board Prof. Aurélien Roux, Full Professor at UniGE, Dr. Dimitri Moreau, Director of ACCESS Geneva (HCS academic platform), and Robert Slooves, partner at Adya. Thanks to FluoSphera's disruptive technology (patent WO2021058557A1), life scientists get an unprecedented level of information at the physiological scale, with affordable products easy to use (kits containing vials of fluorescent-coded tissues). This allows for a better prediction of the toxicity and safety of compounds (drugs, chemicals, cosmetics, etc.) in any laboratory in order to better protect patients and consumers. With this technology, FluoSphera also plans to reduce animal testing and to improve the quality of water (SDG 6). They have evaluated the total market size of the multi-tissue test systems technology to 230 MCHF.
The first kick of CHF 10’000 will support them in recruiting an R&D scientist to start going to the market with a customized service proposed to first adopters, allowing them to design new products and to refine their business model. fluosphera.com
KYLYS: providing patients with highly effective and safe products based on biomolecules
Current hyaluronic acid-based dermal fillers used to correct volume deficiencies and improve facial contours have still several limitations. KYLYS focus on developing a unique dermal filler product with significant competitive advantages due to their innovative technology. KYLYS' team consists of Alexandre Porcello (CEO), Bryan Christopher Porcello (CFO), Dr. Si Gou (Product developer in the frame of the Innosuisse project), and 2 of the initial 3 Founders Dr. Olivier Jordan (CSO ad interim and scientific advisor), Prof. Eric Allémann (scientific advisor). Dr. Patrick Micheels and Dr. Denis Salomon joined the project as key opinion leaders in medical aesthetics. The activity of Kylys gained a brand new dynamic since Alexandre Porcello joined the team in 2020
and Bryan Christopher Porcello in 2021. They are now in charge of the full development of KYLYS. Their technology is already protected by a patent granted in the USA, and benefits from a worldwide I.P cover. The dermal filler products prototypes are developed under an ongoing Innosuisse project. The technology has shown relevant first prototypes with solid PoP/PoC, which brings the company to the status to raise the investment needed to go into the next development stages. This development stage corresponds to Technology Readiness Level 4, in the early development phase of the product. they are looking for Serie A financing for next year to complete all their pre-clinical tests and develop our insights about the market. The Dermal Fillers market size exceeded 3.73 billion in 2019 and is expected to be worth 6.64 billion by 2027 with a 9.3% CAGR.
The Venture Kick financing will support the development of KYLYS for the large-scale production of the product, a safety study in animals, with first steps towards CE marking, and through refinement of the business strategy, product positioning, team building. kylys.com
Publisher Pro: write better scientific papers 50% faster
Publisher Pro, a SaaS platform, is a subscription-based scientific writing ecosystem where scientists produce publishable work, collaborate, and thrive, supported by intuitive software and human editors. Medical researchers must publish in English to stay competitive, but most find writing hard and slow. Writing becomes a bottleneck between doing science and sharing it. Scientists need a reliable system that helps them write quickly and well. About 3 million new English-language medical research manuscripts circulate to journals annually—50% by non-native speakers who face the challenge of writing in English. But even native speakers compete fiercely for places in increasingly selective journals. Courses on scientific writing are rare, expensive, and often poor quality. So are human editors.
Publisher Pro breaks writing tasks into small, manageable components, integrating them into the scientific process. Interactive, highly customizable templates and a rich help system guide authorss. The platform includes specialized tools to painlessly organize writing tasks, manage co-authors, track comments and changes, set and keep deadlines, submit to target journals, and respond to reviewers. Highly-trained editors are on call. The secure, cloud-based platform tracks changes, versions, and provenance. Publisher Pro will charge per-paper fees for use of the platform; human coaching and editing are available as an added service. By their sixth year, they predict USD 38-78 million in gross revenue (based on 5% of market share and low/high estimates of human service hours). The team includes: founder and CEO Kali Tal, Ph.D., designer of the academic writing curriculum at the Medical Library of UniBern; Managing Director Kristin Bivens, Ph.D.; Financial Officer Jasen Best; and Editorial Director Kirsti Cole, Ph.D.
Publisher Pro will use the first 10’000 CHF to structure their company in Switzerland, extend their landing page, broaden their social-media survey-based marketing campaign, and interview key users internationally. pubpro-medhealth.com
Publisher Pro breaks writing tasks into small, manageable components, integrating them into the scientific process. Interactive, highly customizable templates and a rich help system guide authorss. The platform includes specialized tools to painlessly organize writing tasks, manage co-authors, track comments and changes, set and keep deadlines, submit to target journals, and respond to reviewers. Highly-trained editors are on call. The secure, cloud-based platform tracks changes, versions, and provenance. Publisher Pro will charge per-paper fees for use of the platform; human coaching and editing are available as an added service. By their sixth year, they predict USD 38-78 million in gross revenue (based on 5% of market share and low/high estimates of human service hours). The team includes: founder and CEO Kali Tal, Ph.D., designer of the academic writing curriculum at the Medical Library of UniBern; Managing Director Kristin Bivens, Ph.D.; Financial Officer Jasen Best; and Editorial Director Kirsti Cole, Ph.D.
Publisher Pro will use the first 10’000 CHF to structure their company in Switzerland, extend their landing page, broaden their social-media survey-based marketing campaign, and interview key users internationally. pubpro-medhealth.com